So, the great thing for this year for us was that we have a presentation in the Presidential Session, and it’s a very important study in a clinical setting of high unmet need. It refers to osteosarcoma. Osteosarcoma is a very heterogeneous disease, and it’s very difficult to treat. So, unfortunately, we do not have that many treatment opportunities, and that’s why this is really a huge success for us and a great highlight, having an ADC event, so a completely new drug that has been tested in a Phase 3 study, even in osteosarcoma...
So, the great thing for this year for us was that we have a presentation in the Presidential Session, and it’s a very important study in a clinical setting of high unmet need. It refers to osteosarcoma. Osteosarcoma is a very heterogeneous disease, and it’s very difficult to treat. So, unfortunately, we do not have that many treatment opportunities, and that’s why this is really a huge success for us and a great highlight, having an ADC event, so a completely new drug that has been tested in a Phase 3 study, even in osteosarcoma. This is a study for which the preliminary data of the Phase 2 were already presented last year at ASCO and the SARC meeting. It was the Artemis 002. And this year, we have the Phase 3 study, Artemis 011, that evaluated patients receiving ADC with risvutatug rezetecan versus gemcitabine and docetaxel. So, our inclusion criteria were that they should have received at least two treatment lines. And in this comparison with gemcitabine and docetaxel, there was a significant benefit, as centrally assessed, for those patients who were receiving resvuta tucresetecan. It’s, by the way, a B7H3-directed ADC and showed a statistically significant progression-free survival benefit, with 5.5 versus 1.4 months and a hazard ratio of 0.33. Overall response rate and disease control were also substantially higher, and overall survival data were not mature at the time of presentation, but there is a trend showing that there is also an overall survival benefit, or might be an overall survival benefit, despite crossover. Seventeen patients had crossed over from the main arm, from the docetaxel and gemcitabine arm to this arm. Side effects were mainly haematological, but they were mainly haematological in both treatment groups. So, this was our very, the most exciting study that was presented. We had another Phase 3 study. This was the Tangent study, which refers to intermediate tumours. Intermediate tumours are tumours that grow aggressively, but they usually do not metastasise. And in this study, a drug, amaktuzumab, was evaluated in a short-course treatment. So, the patients were receiving intravenous amaktuzumab every two weeks for five cycles, and then they were followed up. Until now, in Europe specifically, we have vimseltinib, which is approved for this disease. And this is a chronic CSF1R receptor TKI. And this is a CSF1 receptor monoclonal antibody that was tested here. And we also have pimicotinib, but by now it’s approved in China, Switzerland and Canada, and pexidartinib, which is approved in the US. So, this is a new concept of a short treatment course for our patients, and it was also exciting to have this data. Of course, it will come down. It was only the six-month data showing a significant benefit when compared to placebo in terms of our response rate. The patient-reported outcomes, which are the most important endpoints for these studies, were significantly better and higher. So, the stiffness, the pain and the range of motion were significantly better with the drug when compared to placebo. Of course, what we are awaiting are the long-term results, the durability of the response, but this is going to be answered in the follow-up over the next 24 months. Then we had a new exciting drug, an EZH2 inhibitor, HH2853. So, this was tested in a Phase 2 study, and due to the fact that tazemetostat, which was the previously available drug for epithelioid sarcoma, was withdrawn by the company in March this year, this was super exciting for us to have a new drug, a new kid on the block, that hopefully might also be available in Europe. The study was performed in China, but the results were very, very promising, showing a high response rate of 40%, progression-free survival of 13.1 months, and overall survival that had not even been reached at the time point of data presentation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.